DK2501234T3 - Fremgangsmåder og sammensætninger til behandling af symptomer forbundet med posttraumatisk belastningsreaktion under anvendelse af cyclobenzaprin - Google Patents

Fremgangsmåder og sammensætninger til behandling af symptomer forbundet med posttraumatisk belastningsreaktion under anvendelse af cyclobenzaprin Download PDF

Info

Publication number
DK2501234T3
DK2501234T3 DK10831895.7T DK10831895T DK2501234T3 DK 2501234 T3 DK2501234 T3 DK 2501234T3 DK 10831895 T DK10831895 T DK 10831895T DK 2501234 T3 DK2501234 T3 DK 2501234T3
Authority
DK
Denmark
Prior art keywords
cyclobenzaprine
pharmaceutical composition
day
ptsd
administered
Prior art date
Application number
DK10831895.7T
Other languages
English (en)
Inventor
Seth Lederman
Herb Harris
Original Assignee
Tonix Pharma Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44059887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2501234(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tonix Pharma Holdings Ltd filed Critical Tonix Pharma Holdings Ltd
Application granted granted Critical
Publication of DK2501234T3 publication Critical patent/DK2501234T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (8)

1. Farmaceutisk sammensætning omfattende cyclobenzaprin i en terapeutisk virksom mængde og en terapeutisk virksom bærer, til anvendelse i en fremgangsmåde til behandling af udvikling af et posttraumatisk belastningsreaktion (PTSD)-symptom eller påbegyndelse af et PTSD-symptom eller konsolidering af et PTSD-symptom eller fortsættelse af et PTSD-symptom efter en traumatisk begivenhed, omfattende at indgive den farmaceutiske sammensætning til et menneske med behov for en sådan behandling, hvor en sådan behandling fjerner eller bedrer PTSD-symptomet, hvor den terapeutisk virksomme mængde af indgivet cyclobenzaprin er mellem 0,5 mg og 50 mg/dag.
2. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor den terapeutisk virksomme mængde af indgivet cyclobenzaprin er mindre end 10 mg/dag.
3. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor den farmaceutiske sammensætning indgives som en oralt opløsende tablet eller som en tynd filmformulering.
4. Farmaceutisk sammensætning til anvendelse ifølge krav 1, yderligere omfattende et lægemiddel udvalgt fra gruppen bestående af en alpha-1-adrenerg receptorantagonist, en beta-adrenerg antagonist, et krampestillende middel, en selektiv serotonin-genoptagelseshæmmer og en serotonin-noradrenalin-genoptagelseshæmmer.
5. Farmaceutisk sammensætning til anvendelse ifølge krav 4, hvor den farmaceutiske sammensætning er en oralt opløsende tablet eller en tynd filmformulering.
6. Farmaceutisk sammensætning omfattende cyclobenzaprin i en terapeutisk virksom mængde og en terapeutisk virksom bærer, til anvendelse i en fremgangsmåde til behandling af en søvnforstyrrelse eller en ikke-søvnforstyrrelse forbundet med posttraumatisk belastningsreaktion (PTSD), omfattende at indgive den farmaceutiske sammensætning til et menneske med behov for en sådan behandling, hvor en sådan behandling bedrer eller fjerner ikke-søvnforstyrrelsen, hvor den terapeutisk virksomme mængde af indgivet cyclobenzaprin er mellem 0,5 mg og 50 mg/dag.
7. Farmaceutisk sammensætning til anvendelse ifølge krav 6, hvor den terapeutisk virksomme mængde af indgivet cyclobenzaprin er mindre end 10 mg/dag.
8. Farmaceutisk sammensætning til anvendelse ifølge krav 6, hvor den farmaceutiske sammensætning indgives som en oralt opløsende tablet eller som en tynd filmformulering.
DK10831895.7T 2009-11-20 2010-11-16 Fremgangsmåder og sammensætninger til behandling af symptomer forbundet med posttraumatisk belastningsreaktion under anvendelse af cyclobenzaprin DK2501234T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28166109P 2009-11-20 2009-11-20
PCT/US2010/002979 WO2011062614A1 (en) 2009-11-20 2010-11-16 Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine

Publications (1)

Publication Number Publication Date
DK2501234T3 true DK2501234T3 (da) 2017-12-04

Family

ID=44059887

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10831895.7T DK2501234T3 (da) 2009-11-20 2010-11-16 Fremgangsmåder og sammensætninger til behandling af symptomer forbundet med posttraumatisk belastningsreaktion under anvendelse af cyclobenzaprin

Country Status (14)

Country Link
US (2) US9918948B2 (da)
EP (1) EP2501234B1 (da)
CY (1) CY1119698T1 (da)
DK (1) DK2501234T3 (da)
ES (1) ES2649022T3 (da)
HR (1) HRP20171739T1 (da)
HU (1) HUE037281T2 (da)
LT (1) LT2501234T (da)
NO (1) NO2501234T3 (da)
PL (1) PL2501234T3 (da)
PT (1) PT2501234T (da)
RS (1) RS56634B1 (da)
SI (1) SI2501234T1 (da)
WO (1) WO2011062614A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2501234T (lt) 2009-11-20 2017-12-11 Tonix Pharma Holdings Limited Būdai ir kompozicijos, skirti simptomų, susijusių su potrauminiu streso sutrikimu, gydymui naudojant ciklobenzapriną
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
CN104684550A (zh) * 2012-06-15 2015-06-03 通尼克斯制药有限公司 用于跨粘膜吸收的组合物和方法
PT2968992T (pt) 2013-03-15 2020-02-18 Tonix Pharma Holdings Ltd Formulações eutécticas de cloridrato de ciclobenzaprina e manitol
DK3091997T5 (da) 2014-01-10 2024-10-14 Bioverativ Therapeutics Inc Kimære faktor viii-proteiner og anvendelser deraf
MX2017003644A (es) 2014-09-18 2017-10-31 Tonix Pharma Holdings Ltd Formulaciones eutecticas de clorhidrato de ciclobenzaprina.
US11826321B2 (en) 2017-12-11 2023-11-28 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
NZ769677A (en) 2018-05-18 2024-07-05 Bioverativ Therapeutics Inc Methods of treating hemophilia a
TW202019400A (zh) * 2018-08-20 2020-06-01 愛爾蘭商托尼克製藥控股有限公司 治療急性壓力症候群及創傷後壓力症候群之方法
EP3883546A1 (en) 2018-11-21 2021-09-29 Rosemont Pharmaceuticals Ltd Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
JP7088153B2 (ja) * 2019-09-19 2022-06-21 カシオ計算機株式会社 Ｃａｐ（周期性脳波活動）検出装置、ｃａｐ（周期性脳波活動）検出方法及びプログラム
JP2023521167A (ja) * 2020-04-08 2023-05-23 トニックス ファーマシューティカルズ ホールディング コーポレーション 性機能障害のシクロベンザプリン処置
JP2023554597A (ja) 2020-11-20 2023-12-28 トニックス ファーマシューティカルズ ホールディング コーポレイション アルコール使用障害のためのシクロベンザプリン処置

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968507A (en) 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
CA2155947C (en) 1993-02-22 2007-08-21 Mark W. Grinstaff Methods for in vivo delivery of biologics and compositions useful therefor
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999018937A1 (en) 1997-10-16 1999-04-22 Merck & Co., Inc. New cyclobenzaprine composition
PT1077683E (pt) 1998-05-14 2003-04-30 Alza Corp Terapia anti-depressiva
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6358944B1 (en) * 1999-08-13 2002-03-19 Vela Pharmaceuticals, Inc. Methods and compositions for treating generalized anxiety disorder
WO2001012175A1 (en) 1999-08-13 2001-02-22 Vela Pharmaceuticals Inc. Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
WO2001089476A1 (en) 2000-05-19 2001-11-29 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
PT1441708E (pt) 2001-11-05 2009-06-18 Krele Pharmaceuticals Llc Composições e métodos para aumentar a observância de terapias utilizando inibidores da aldeído desidrogenase e para tratar alcoolismo
US7105486B2 (en) 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7038085B2 (en) * 2002-10-25 2006-05-02 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
EP3470084A1 (en) 2002-12-09 2019-04-17 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
BRPI0410792B8 (pt) 2003-05-29 2021-05-25 New River Pharmaceuticals Inc compostos de anfetamina resistentes à dependencia
EP1685115A1 (en) 2003-11-03 2006-08-02 Warner-Lambert Company LLC Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
US20050143350A1 (en) 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
JP2007516259A (ja) 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
JP5179757B2 (ja) 2004-02-17 2013-04-10 トランセプト ファーマシューティカルズ， インコーポレイティド 口腔粘膜を介して催眠剤をデリバリーするための組成物及びその使用方法
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US7532935B2 (en) 2005-07-29 2009-05-12 Cyberonics, Inc. Selective neurostimulation for treating mood disorders
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20090069267A1 (en) * 2006-01-17 2009-03-12 Abrams Daniel J Central administration of stable formulations of therapeutic agents for cns conditions
US20080146672A1 (en) 2006-12-08 2008-06-19 Denton Marcia Marye Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue
WO2009002770A1 (en) * 2007-06-22 2008-12-31 Merck & Co., Inc. 6.5-pyrrolopiperidine tachykinin receptor antagonists
WO2009015248A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics Treatment of post-traumatic stress disorder
US20090060983A1 (en) 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
DK2200588T3 (da) 2007-09-25 2019-07-01 Solubest Ltd Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf
WO2009058950A2 (en) 2007-10-30 2009-05-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
US20090148532A1 (en) 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
CA3066426A1 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
US20100266682A1 (en) 2008-12-10 2010-10-21 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
EP2233134A1 (en) 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
US20100247586A1 (en) 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
US8343533B2 (en) 2009-09-24 2013-01-01 Mcneil-Ppc, Inc. Manufacture of lozenge product with radiofrequency
LT2501234T (lt) 2009-11-20 2017-12-11 Tonix Pharma Holdings Limited Būdai ir kompozicijos, skirti simptomų, susijusių su potrauminiu streso sutrikimu, gydymui naudojant ciklobenzapriną
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
KR20130132774A (ko) 2010-09-01 2013-12-05 토닉스 파마슈티컬스, 아이엔씨. 코카인 중독에 대한 치료
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
CN104684550A (zh) 2012-06-15 2015-06-03 通尼克斯制药有限公司 用于跨粘膜吸收的组合物和方法
PT2968992T (pt) 2013-03-15 2020-02-18 Tonix Pharma Holdings Ltd Formulações eutécticas de cloridrato de ciclobenzaprina e manitol
MX2017003644A (es) 2014-09-18 2017-10-31 Tonix Pharma Holdings Ltd Formulaciones eutecticas de clorhidrato de ciclobenzaprina.

Also Published As

Publication number Publication date
US20110124656A1 (en) 2011-05-26
CY1119698T1 (el) 2018-04-04
EP2501234B1 (en) 2017-09-13
RS56634B1 (sr) 2018-03-30
ES2649022T3 (es) 2018-01-09
LT2501234T (lt) 2017-12-11
SI2501234T1 (en) 2018-02-28
PL2501234T3 (pl) 2018-01-31
HRP20171739T1 (hr) 2018-03-09
PT2501234T (pt) 2017-12-13
WO2011062614A1 (en) 2011-05-26
NO2501234T3 (da) 2018-02-10
US20180193288A1 (en) 2018-07-12
EP2501234A4 (en) 2013-04-24
EP2501234A1 (en) 2012-09-26
US9918948B2 (en) 2018-03-20
HUE037281T2 (hu) 2018-08-28

Similar Documents

Publication Publication Date Title
DK2501234T3 (da) Fremgangsmåder og sammensætninger til behandling af symptomer forbundet med posttraumatisk belastningsreaktion under anvendelse af cyclobenzaprin
US10722478B2 (en) Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
AU2020203874B2 (en) Methods and compositions for treating depression using cyclobenzaprine
CN114206349A (zh) 治疗神经认知障碍、慢性疼痛及减轻炎症的方法
US20180325844A1 (en) Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
US20230233485A1 (en) Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females
US20230165847A1 (en) Methods of use of t-type calcium channel modulators
AI Iskandarov et al. THE MEDICAL SIGNIFICANCE OF PSYCHOTROPIC SUBSTANCES PEMOLINE, FENCAMPHAMINE, AND FENPROPOREX
NZ714294B2 (en) Methods And Compositions For Treating Depression Using Cyclobenzaprine
Molina Trullàs Use of MDMA in the treatment of Post-traumatic Stress Disorder
Conroy et al. Sleep in substance use disorders
US20130267533A1 (en) 5ht1a agonists for treatment of high cholesterol
Hysek et al. Effects of MDMA on the pupillary light reflex on its own and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin